Skip to the main content

Liječnički vjesnik, Vol. 145 No. Supp 2, 2023.

Meeting abstract

https://doi.org/10.26800/LV-145-supl2-CR62

Personalized approach to patients with statin intolerance based on pharmacogenomics (function of OATP1B1 protein)

Anja Ćuk ; School of Medicine, University of Zagreb, Zagreb, Croatia
Doroteja Đekić
Dunja Leskovar
Livija Šimičević

Full text: english pdf 290 Kb

page 77-77

downloads: 163

cite

Abstract

Statins, HMG CoA reductase inhibitors, are effective at lowering blood cholesterol levels and protecting against cardiovascular incidents. Their uptake into hepatocytes depends on the activity of the SLCO1B1 gene which codes for the OATP1B1 transporter protein. Pharmacogenomic testing provides us information about the activity level of a certain protein. Lowered activity level of OATP1B1 protein can prolong the bioavailability of some drugs, such as statins. This greater systemic exposure to statins carries a higher risk of intolerance symptoms when compared to normal function of the OATP1B1 protein.

Keywords

dyslipidemia; hmg coa statins; OATP1B1 protein, human; pharmacogenomics

Hrčak ID:

303984

URI

https://hrcak.srce.hr/303984

Publication date:

23.4.2023.

Visits: 532 *